18/12/2014 – Deal facilitated between Lions Eye Institute and Experimentica…more

22/09/2014 – Deal facilitated between Children’s Cancer Institute and Abcam…more

06/08/2014 – Engagement by Mirrx Therapeutics (Denmark) to partner its proprietary Blockmir technology platform

24/05/2014 - Deal facilitated between a EU specialty biopharma company and the Lions Eye Institute…more

12/05/2014 – Engagement by LiPlasome Pharma (Denmark) to partner LiPlaCis®, a phase I/II clinical candidate for cancer…more

27/01/2015 – Prof. John Christodoulou and his team at Children’s Hospital Westmead have generated exciting in vivo proof of principle data, showing that their GM probiotic significantly limits phenylalanine blood levels after protein consumption by PahENU2 mice (a model of phenylketonuria, PKU), offering the prospect of developing an efficacious, orally bioavailable probiotic for PKU patients.

23/08/2014 – Professor Michelle Haber AM, Director of Children’s Cancer Institute, has been awarded the NSW Premier’s Award for Outstanding Cancer Researcher of the Year 2014, in recognition of her significant contribution to research into childhood cancer.